Results 181 to 190 of about 74,680 (298)

Potentially inappropriate medication use among older outpatients-prevalence and contributing factors: a retrospective study. [PDF]

Sao Paulo Med J
Bozkurt ME, Ozturk E.
europepmc   +1 more source

Tirzepatide Persistence and Associated Changes in Clinical Outcomes in US Adults With Obesity or Overweight: A 6‐Month Claims Database Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Tirzepatide is a once‐weekly glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) approved in the US for the treatment of Type 2 diabetes (T2D), weight loss and obstructive sleep apnoea. This study aimed to assess the utilisation and effectiveness of tirzepatide among individuals in a large ...
Theresa Hunter Gibble, Malvika Venkataraman, Donna Mojdami, Carlos Vallarino, Grace Stockbower, Michael Grabner, Mythili Ananth, Karishma Desai   +7 more
wiley   +1 more source

Association between polypharmacy and clinical outcomes in children with medical complexity: a retrospective cohort study. [PDF]

Front Pediatr
Shao S, Hu K, Zhou J.
europepmc   +1 more source

Dyslipidaemia, Chronic Kidney Disease and Diabetes Mellitus: A Triple Threat to Cardiovascular Health

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Diabetes mellitus (DM) and chronic kidney disease (CKD) frequently coexist and together create a ‘triple threat’ with dyslipidaemia, enhancing the risk for cardiovascular morbidity and mortality. Diabetic kidney disease (DKD) leads to altered lipid metabolism through insulin resistance, inflammation and oxidative stress resulting in an ...
Ann S. Forrest, Priyanka Majety, Stéphanie B. Mayer, Om P. Ganda   +3 more
wiley   +1 more source

Comparison of existing polypharmacy measures to a measure incorporating all modes of administration: an observational study using routinely collected data. [PDF]

Int J Clin Pharm
Lim D, Youens D, Moorin R, Stafford A.
europepmc   +1 more source

Hospitalisation Is a Strong Risk Factor for Discontinuation of Sodium‐Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are commonly withheld during hospitalisation because of concerns about diabetic ketoacidosis. We examined whether hospitalisation was associated with discontinuation of SGLT2i and compared patterns with another anti‐hyperglycaemic medicine without similar inpatient safety concerns ...
Tamara Y. Milder, Leah Shepherd, Hans Kristian Raket, Jerry R. Greenfield, Richard O. Day, Jialing Lin, Juliana de Oliveira Costa, Sophie Stocker, Carol A. Pollock, Brendon Neuen, Min Jun, Jane Ludington, Sallie‐Anne Pearson, Michael O. Falster   +13 more
wiley   +1 more source

Plasma NfL and sCD14 Are Associated with Polypharmacy and Recurrent Falls in Virally Suppressed Older People with HIV. [PDF]

J Acquir Immune Defic Syndr
Kosana P, Grubman A, Shen G, Wu K, Tassiopoulos K, Ma Q, Letendre S, Erlandson KM, Farhadian SF, ACTG A5322 HAILO team.   +9 more
europepmc   +1 more source

The SGLT2i Treatment Gap in UK Primary Care: A Cross‐Sectional RWE Study of Prescribing in Clinical Practice

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) improve cardiovascular and renal outcomes in type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD) and chronic heart failure (CHF). Despite clinical guideline recommendations, SGLT2i uptake in UK primary care remains suboptimal and information on utilisation is limited.
Chelsea Stefanska, Ryan Chung, Salman Ramjaun, Danyao Jin, Ciara Doherty, Kieran McCafferty, Samuel Seidu   +6 more
wiley   +1 more source

Medication safety in older adults in India: an integrative PhD synthesis of direct evidence and contextual implementation evidence. [PDF]

Glob Health Action
Das S.
europepmc   +1 more source

Experimental peptides, GLP‐1s and polypharmacy: Future directions for image‐ and performance‐enhancing drug harm reduction

Addiction, EarlyView.
Luke A. Turnock, Lambros Lazuras
wiley   +1 more source